Abbott Labs Files 8-K on Q1 Financials

TL;DR

Abbott Labs dropped its Q1 2024 8-K, check the financials.

AI Summary

Abbott Laboratories filed an 8-K on April 17, 2024, reporting on its results of operations and financial condition. The filing covers the period from January 1, 2024, to March 31, 2024. Specific financial details and exhibits related to this period are included in the report.

Why It Matters

This filing provides investors with crucial, up-to-date financial information for Abbott Laboratories, impacting investment decisions and market perception.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any unusual risks or events.

Key Players & Entities

• ABBOTT LABORATORIES (company) — Registrant
• April 17, 2024 (date) — Date of Report
• January 1, 2024 (date) — Start of Reporting Period
• March 31, 2024 (date) — End of Reporting Period
• 100 Abbott Park Road (address) — Principal Executive Offices
• Abbott Park, Illinois 60064-6400 (address) — Principal Executive Offices Location

FAQ

Filing Documents

• abt-20240417.htm (8-K) — 28KB
• abt-2024q1xexhibitx991.htm (EX-99.1) — 414KB
• image.jpg (GRAPHIC) — 1KB
• 0001628280-24-016497.txt ( ) — 626KB
• abt-20240417.xsd (EX-101.SCH) — 2KB
• abt-20240417_def.xml (EX-101.DEF) — 15KB
• abt-20240417_lab.xml (EX-101.LAB) — 26KB
• abt-20240417_pre.xml (EX-101.PRE) — 16KB
• abt-20240417_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On April 17, 2024 , Abbott Laboratories announced its results of operations for the first quarter 2024. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, cost reduction initiatives, fair value adjustments to the contingent consideration related to business acquisitions, impairment charges related to intangible assets or equity investments, certain regulatory costs, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott's management internally assesses performance. Abbott's management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott's results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott's management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits Exhibit No. Exhibit 99.1 Press Release dated April 17, 2024 (furnished pursuant to Item 2.02). 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBOTT LABORATORIES Date: April 17, 2024 By: /s/ Philip P. Boudreau Philip P. Boudreau Senior Vice President, Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR